Buľková V., Vargová J., Babinčák M., Jendželovský R., Zdráhal Z., Roudnický P., Košuth J., Fedoročko P. New findings on the action of hypericin in hypoxic cancer cells with a focus on the modulation of side population cells. In Biomedicine and Pharmacotherapy, 2023, 163, 114829.

Nagy Ľ., Zeleňáková A., Hrubovčák P., Barutiak M., Lisnichuk M., Bednarčík J., Vargová J., Jendželovský R., Ševc J., Vilček Š. The role of pH on the preparation of citric acid coated cobalt ferrite nanoparticles for biomedical applications. In Journal of Alloys and Compounds, 2023, 960,170833.

Majerník M., Jendželovský R., Vargová J., Jendželovská Z., Fedoročko P. Multifunctional Nanoplatforms as a Novel Effective Approach in Photodynamic Therapy and Chemotherapy, to Overcome Multidrug Resistance in Cancer. In Pharmaceutics, 2022, 14(5):1075.

Babinčák M., Jendželovský R., Košuth J., Majerník M., Vargová J., Mikulášek K., Zdráhal Z., Fedoročko P. Death Receptor 5 (TNFRSF10B) Is Upregulated and TRAIL Resistance Is Reversed in Hypoxia and Normoxia in Colorectal Cancer Cell Lines after Treatment with Skyrin, the Active Metabolite of Hypericum spp. In Cancers (Basel), 2021,13(7).

Konkoľová E., Hudáčová M., Hamuľaková S., Jendželovský R., Vargová J., Ševc J., Fedoročko P., Kožurková M. Tacrine-Coumarin Derivatives as Topoisomerase Inhibitors with Antitumor Effects on A549 Human Lung Carcinoma Cancer Cell Lines. In Molecules, 2021, 26(4):1133.

Hudáčová M, Hamuľaková S, Konkoľová E, Jendželovský R, Vargová J, Ševc J, Fedoročko P, Soukup O, Janočková J, Ihnatova V, Kučera T, Bzonek P, Novakova N, Jun D, Junova L, Korábečný J, Kuča K, Kožurková M. Synthesis of New Biscoumarin Derivatives, In Vitro Cholinesterase Inhibition, Molecular Modelling and Antiproliferative Effect in A549 Human Lung Carcinoma Cells. In Int J Mol Sci. 2021, 22(8):3830.

Nunhart P, Konkoľová E, Janovec L, Jendželovský R, Vargová J, Ševc J, Matejová M, Miltáková B, Fedoročko P, Kozurkova M. Fluorinated 3,6,9-trisubstituted acridine derivatives as DNA interacting agents and topoisomerase inhibitors with A549 antiproliferative activity. In Bioorg Chem., 2020, 94:103393.

EPIC-XS-0000051 (p.n. 823839, The European Proteomics Infrastructure Consortium providing access) funded by the Horizon 2020 programme of the European Union: ProSiPo (Proteomics of the Side Population): Comparative proteomic analysis of side and non-side populations isolated from A549 lung carcinoma cells cultivated under normoxic and hypoxic conditions.

Co-investigator of the project VEGA 1/0003/23: Changes in the regulation of BCRP transport protein expression and activity in relation to the proangiogenic and metastatic potential of cancer cells. Principal investigator: prof. RNDr. Peter Fedoročko, CSc. 2023 – 2026

Co-investigator of the project: „Nanočastice pre riešenie diagnosticko-terapeutických problémov s COVID-19 (NANOVIR)". Operational Programme Integrated Infrastructure, project “NANOVIR”, ITMS:313011AUW7, co-funded by ERDF. 01/2021 – 06/2023; Principal investigator: doc. RNDr. Adriana Zeleňáková, PhD.

Co-investigator of the project APVV-18/0125 Novel anthraquinones from natural sources for biomedical applications, 2019 –2023. Principal inestigator: prof. RNDr. Eva Čellárová, DrSc

Co-investigator of the project: Open scientific community for modern interdisciplinary research in medicine (OPENMED, ITMS2014+: 313011V455). 11/2019 - 6/2023

Co-investigator of the project VEGA 1/0022/19:Hypoxia and polymorphism of BCRP transporter as the factors affecting hypericin accumulation and efficiency in vitro and ex ovo, 2019 – 2022. Principal investigator: prof. RNDr. Peter Fedoročko, CSc.